Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Agios Pharmaceuticals, Inc. - Common Stock (NQ:AGIO)

39.25 +1.54 (+4.08%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 630,463
Open 38.00
Bid (Size) 37.98 (1)
Ask (Size) 40.00 (10)
Prev. Close 37.71
Today's Range 37.81 - 39.37
52wk Range 23.41 - 62.58
Shares Outstanding 58,951,469
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
10 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
Agios Retail Buzz Surges On Saudi Thalassemia Nod As Retail Hails ‘Incredible Recovery’ Despite FDA Concerns
Via Stocktwits

Performance

YTD
+23.3%
+23.3%
1 Month
+8.5%
+8.5%
3 Month
+17.6%
+17.6%
6 Month
+17.6%
+17.6%
1 Year
-12.3%
-12.3%

More News

Read More
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Traders are paying attention to the gapping stocks in Monday's session.
Via Chartmill
Earnings Scheduled For July 31, 2025
Via Benzinga
Earnings Scheduled For May 1, 2025
Via Benzinga
An Overview of Agios Pharmaceuticals's Earnings
Via Benzinga
Earnings Scheduled For February 13, 2025
Via Benzinga
Analyst Ratings For Agios Pharmaceuticals
Via Benzinga
What's going on in today's pre-market session
Via Chartmill
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Agios (AGIO) Q2 Revenue Jumps 45%
Via The Motley Fool
Topics Intellectual Property
Agios Pharmaceuticals Inc (NASDAQ:AGIO) Reports Mixed Q2 2025 Results: Revenue Beat but Wider EPS Loss
Via Chartmill
Deep Dive Into Alnylam Pharmaceuticals Stock: Analyst Perspectives (6 Ratings)
Via Benzinga
Earnings Preview: Agios Pharmaceuticals
Via Benzinga
4 Analysts Have This To Say About Agios Pharmaceuticals
Via Benzinga
Agios Pharmaceuticals Reveals Encouraging Data From Rare Blood Disorder Study In Younger Patients Aged Below 18 Years
Via Benzinga
Tesla, Micron, Broadcom, MARA Holdings And Other Big Stocks Moving Higher On Monday
Via Benzinga
Agios Crashes 19% After A Surprise Side Effect Hammered Its 'Very Safe' Drug
Via Investor's Business Daily
This HP Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday
Via Benzinga
Micron To $150? Here Are 10 Top Analyst Forecasts For Friday
Via Benzinga
Expert Ratings For Agios Pharmaceuticals
Via Benzinga
Pfizer Tanked A $5.4 Billion Takeover. Why Crispr, Agios, Beam Could Benefit.
Via Investor's Business Daily
Agios Pharmaceuticals' Rare Blood Disorder Drug Misses Primary Goal In Pediatric Study, Stock Slides
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga

Frequently Asked Questions

Is Agios Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, Agios Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does Agios Pharmaceuticals, Inc. - Common Stock trade on?
Agios Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Agios Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for Agios Pharmaceuticals, Inc. - Common Stock is AGIO on the Nasdaq Stock Market
What is the current price of Agios Pharmaceuticals, Inc. - Common Stock?
The current price of Agios Pharmaceuticals, Inc. - Common Stock is 39.25
When was Agios Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of Agios Pharmaceuticals, Inc. - Common Stock was at 09/02/25 04:00 PM ET
What is the market capitalization of Agios Pharmaceuticals, Inc. - Common Stock?
The market capitalization of Agios Pharmaceuticals, Inc. - Common Stock is 2.31B
How many shares of Agios Pharmaceuticals, Inc. - Common Stock are outstanding?
Agios Pharmaceuticals, Inc. - Common Stock has 2B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.